as suspected not black and white outcome which is typical for trials data
but the key will be if TGA accepts the data for schedule 3 being granted - then it is a completely different ball game as all CND currently prescribed under Special Access Scheme for insomnia will not be able to be supplied - the Schedule 3 BOD product would be only product that can be supplied and that would be over the counter at any chemist so that would be a big outcome.
smy read is still in the game and way further down track it seems than competitors - if value of schedule 3 is X and it has been discounted significantly to date, then that discount has to change on back of these findings and stock should re-rate up to reflect lower discount to potential ,commercialisation value .....
- Forums
- ASX - By Stock
- Ann: Schedule 3 CBD trial preliminary results
as suspected not black and white outcome which is typical for...
-
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable